share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GUYER DAVID R

SEC ·  Jun 5 04:35
Summary by Futu AI
On June 3, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a series of transactions involving the company's common stock. Guyer acquired a total of 9,775 shares through the exercise or conversion of derivative securities at prices ranging from $3.26 to $3.50 per share. On the same day, he sold 11,625 shares in an open market transaction at a price of $10.2972 per share, resulting in a total market value of $119,704.95 for the disposed shares. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals decreased to 3,700 shares.
On June 3, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], completed a series of transactions involving the company's common stock. Guyer acquired a total of 9,775 shares through the exercise or conversion of derivative securities at prices ranging from $3.26 to $3.50 per share. On the same day, he sold 11,625 shares in an open market transaction at a price of $10.2972 per share, resulting in a total market value of $119,704.95 for the disposed shares. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals decreased to 3,700 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.